The World Health Organization's global strategy for prevention and assessment of HIV drug resistance
- 1 February 2008
- journal article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 13 (2_suppl) , 1-13
Abstract
Antiretroviral treatment (ART) for HIV is being scaled up rapidly in resource-limited countries. Treatment options are simplified and standardized, generally with one potent first-line regimen and one potent alternate first-line regimen recommended. Widespread HIV drug resistance (HIVDR) was initially feared, but reports from resource-limited countries suggest that initial ART programmes are as effective as in resource-rich countries, which should limit HIV drug resistance if programme effectiveness continues during scale-up. ART interruptions must be minimized to maintain viral suppression on the first-line regimen for as long as possible. Lack of availability of appropriate second-line drugs is a concern, as is the additional accumulation of resistance mutations in the absence of viral load testing to determine failure. The World Health Organization (WHO) recommends a minimum-resource strategy for prevention and assessment of HIVDR in resource-limited countries. The WHO's Global Network HIVResNet provides standardized tools, training, technical assistance, laboratory quality assurance, analysis of results and recommendations for guidelines and public health action. National strategies focus on assessments to guide immediate public health action to improve ART programme effectiveness in minimizing HIVDR and to guide regimen selection. Globally, WHO HIVResNet collects and analyses data to support evidence-based international policies and guidelines. Financial support is provided by major international organizations and technical support from HIVDR experts worldwide. As of December 2007, 25 countries were planning or implementing the strategy; seven countries report results in this supplement.Keywords
This publication has 76 references indexed in Scilit:
- International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 updateAmerican Journal of Obstetrics and Gynecology, 2007
- Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter?American Journal of Obstetrics and Gynecology, 2007
- HIV Prevention for a Threatened ContinentJAMA, 2006
- Treatment for Adult HIV InfectionJAMA, 2006
- The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settingsThe Lancet, 2006
- Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessmentThe Lancet, 2006
- Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countriesThe Lancet, 2006
- Treatment of antiretroviral-drug-resistant HIV-1 infectionThe Lancet, 2003
- Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort StudyThe Lancet, 2001
- Reduced replication of 3TC‐resistant HIV‐1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.The EMBO Journal, 1996